Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Enochian BiosciencesLotus PharmaceuticalsAssembly BiosciencesInfinity PharmaceuticalsStrongbridge Biopharma
SymbolNASDAQ:ENOBOTCMKTS:LTUSNASDAQ:ASMBNASDAQ:INFINASDAQ:SBBP
Price Information
Current Price$3.34$0.05$4.09$2.78$2.39
52 Week RangeN/AN/ABuyBuyBuy
MarketRank™
Overall Score0.50.01.61.61.5
Analysis Score0.00.03.34.43.5
Community Score0.00.02.32.02.3
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.70.80.8
Earnings & Valuation Score0.60.00.60.60.6
Analyst Ratings
Consensus RecommendationN/AN/ABuyBuyBuy
Consensus Price TargetN/AN/A$11.50$9.00$7.00
% Upside from Price TargetN/AN/A181.17% upside223.74% upside192.89% upside
Trade Information
Market Cap$159.53 million$117.78 million$163.84 million$246.42 million$161.43 million
Beta0.51.290.612.41.91
Average Volume265,710164,7081,219,2713,577,7381,047,946
Sales & Book Value
Annual RevenueN/AN/A$15.96 million$3.05 million$21.71 million
Price / SalesN/AN/A10.2780.797.44
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$3.58 per shareN/A$10.49 per share$0.14 per share$1.33 per share
Price / BookN/AN/A0.3919.861.80
Profitability
Net Income$-11,420,000.00N/A$-97,630,000.00$-47,060,000.00$-49,450,000.00
EPSN/AN/A($3.72)($0.83)($1.10)
Trailing P/E Ratio0.000.00N/AN/AN/A
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-60.14%-2,592.65%-149.79%
Return on Equity (ROE)-5.79%N/A-18.75%-1,358.77%-65.85%
Return on Assets (ROA)-5.47%N/A-15.89%-81.85%-38.81%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.04%N/AN/AN/A0.10%
Current Ratio7.29%N/A14.66%4.42%4.51%
Quick Ratio7.29%N/A14.66%4.42%4.45%
Ownership Information
Institutional Ownership Percentage5.11%N/A92.23%46.66%58.27%
Insider Ownership Percentage69.60%N/A7.10%13.77%6.60%
Miscellaneous
Employees102331392572
Shares Outstanding47.76 million2.94 billion40.06 million88.64 million67.55 million
Next Earnings Date5/10/2021 (Estimated)N/A5/6/2021 (Estimated)5/10/2021 (Estimated)5/5/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Strongbridge Biopharma plc (NASDAQ:SBBP) Short Interest Up 47.2% in MarchStrongbridge Biopharma plc (NASDAQ:SBBP) Short Interest Up 47.2% in March
americanbankingnews.com - April 17 at 7:28 AM
Strongbridge Biopharma plc (NASDAQ:SBBP) Expected to Post Quarterly Sales of $8.22 MillionStrongbridge Biopharma plc (NASDAQ:SBBP) Expected to Post Quarterly Sales of $8.22 Million
americanbankingnews.com - April 14 at 11:08 AM
Strongbridge Biopharma plc (NASDAQ:SBBP) surprises Wall Street with -6.08% stock price lossStrongbridge Biopharma plc (NASDAQ:SBBP) surprises Wall Street with -6.08% stock price loss
marketingsentinel.com - April 13 at 11:35 AM
Strongbridge Biopharma plc (NASDAQ:SBBP) Expected to Announce Earnings of -$0.10 Per ShareStrongbridge Biopharma plc (NASDAQ:SBBP) Expected to Announce Earnings of -$0.10 Per Share
americanbankingnews.com - April 12 at 12:18 PM
Strongbridges Recorlev Shows Improvements in Cortisol Control In Cushings Syndrome, DiabetesStrongbridge's Recorlev Shows Improvements in Cortisol Control In Cushing's Syndrome, Diabetes
finance.yahoo.com - April 8 at 12:19 PM
Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 ...Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 ...
apnews.com - April 7 at 8:23 PM
Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 SONICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in Frontiers in EndocrinologyStrongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 SONICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in Frontiers in Endocrinology
finance.yahoo.com - April 7 at 8:23 PM
 Analysts Expect Strongbridge Biopharma plc (NASDAQ:SBBP) Will Post Quarterly Sales of $8.22 Million Analysts Expect Strongbridge Biopharma plc (NASDAQ:SBBP) Will Post Quarterly Sales of $8.22 Million
americanbankingnews.com - March 27 at 3:56 AM
Strongbridge Biopharma plc (NASDAQ:SBBP) 38.04% Above its 52-week Low, How Long Will it Keep Rising?Strongbridge Biopharma plc (NASDAQ:SBBP) 38.04% Above its 52-week Low, How Long Will it Keep Rising?
marketingsentinel.com - March 25 at 9:56 AM
Strongbridge Gains on ResultsStrongbridge Gains on Results
baystreet.ca - March 22 at 3:31 PM
SBBP Stock Price Increases Over 25% Pre-Market: Why It HappenedSBBP Stock Price Increases Over 25% Pre-Market: Why It Happened
pulse2.com - March 22 at 9:55 AM
Strongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of ...Strongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of ...
apnews.com - March 21 at 8:23 AM
Strongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2021 Annual Meeting of the Endocrine Society (ENDO)Strongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2021 Annual Meeting of the Endocrine Society (ENDO)
finance.yahoo.com - March 20 at 2:15 PM
Strongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2021 Annual Meeting...Strongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2021 Annual Meeting...
markets.businessinsider.com - March 20 at 11:23 AM
Strongbridge Biopharma plc to Present at Oppenheimer’s 31st Annual Healthcare ConferenceStrongbridge Biopharma plc to Present at Oppenheimer’s 31st Annual Healthcare Conference
finance.yahoo.com - March 15 at 9:15 AM
Strongbridge Biopharma plc to Present at Oppenheimers 31st Annual Healthcare ConferenceStrongbridge Biopharma plc to Present at Oppenheimer's 31st Annual Healthcare Conference
feeds.benzinga.com - March 15 at 8:20 AM
Strongbridge Biopharma plc (NASDAQ:SBBP) Analysts Are Pretty Bullish On The Stock After Recent ResultsStrongbridge Biopharma plc (NASDAQ:SBBP) Analysts Are Pretty Bullish On The Stock After Recent Results
finance.yahoo.com - March 5 at 9:04 AM
Strongbridge Biopharma files new drug application with FDA for rare disease therapyStrongbridge Biopharma files new drug application with FDA for rare disease therapy
bizjournals.com - March 3 at 5:01 PM
Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2020 Financial Results and ...Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2020 Financial Results and ...
apnews.com - March 3 at 12:00 PM
Recap: Strongbridge Biopharma Q4 EarningsRecap: Strongbridge Biopharma Q4 Earnings
benzinga.com - March 3 at 12:00 PM
Strongbridge Biopharma: Q4 Earnings SnapshotStrongbridge Biopharma: Q4 Earnings Snapshot
finance.yahoo.com - March 3 at 12:00 PM
Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate UpdateStrongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - March 3 at 12:00 PM
Strongbridge Biopharma: Q4 Earnings Snapshot | Raleigh News & ObserverStrongbridge Biopharma: Q4 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - March 3 at 12:00 PM
Preview: Strongbridge Biopharmas EarningsPreview: Strongbridge Biopharma's Earnings
benzinga.com - March 2 at 12:42 PM
Strongbridge Biopharma plc Announces Submission of New Drug Application for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to the U.S. Food & Drug AdministrationStrongbridge Biopharma plc Announces Submission of New Drug Application for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to the U.S. Food & Drug Administration
finance.yahoo.com - March 2 at 12:42 PM
DateCompanyBrokerageAction
3/29/2021Assembly BiosciencesSVB LeerinkReiterated Rating
3/2/2021Assembly BiosciencesTruistLower Price Target
2/28/2021Assembly BiosciencesRobert W. BairdReiterated Rating
2/25/2021Assembly BiosciencesMizuhoReiterated Rating
11/6/2020Assembly BiosciencesJefferies Financial GroupDowngrade
6/25/2020Assembly BiosciencesWilliam BlairReiterated Rating
9/19/2019Assembly BiosciencesChardan CapitalReiterated Rating
3/24/2021Infinity PharmaceuticalsTruist SecuritiesInitiated Coverage
3/23/2021Infinity PharmaceuticalsB. RileyLower Price Target
3/23/2021Infinity PharmaceuticalsWells Fargo & CompanyBoost Price Target
3/18/2021Infinity PharmaceuticalsTruist FinancialInitiated Coverage
2/25/2021Infinity PharmaceuticalsPiper SandlerInitiated Coverage
2/11/2021Infinity PharmaceuticalsOppenheimerBoost Price Target
2/5/2021Infinity PharmaceuticalsJPMorgan Chase & Co.Upgrade
6/27/2019Infinity PharmaceuticalsCIBCInitiated Coverage
1/7/2019Infinity PharmaceuticalsUBS GroupReiterated Rating
3/4/2021Strongbridge BiopharmaHC WainwrightReiterated Rating
3/3/2020Strongbridge BiopharmaCraig HallumInitiated Coverage
9/24/2019Strongbridge BiopharmaEvercore ISIInitiated Coverage
2/26/2019Strongbridge BiopharmaCantor FitzgeraldSet Price Target
12/18/2018Strongbridge BiopharmaLaidlawInitiated Coverage
8/9/2018Strongbridge BiopharmaJMP SecuritiesBoost Price Target
8/8/2018Strongbridge BiopharmaJanney Montgomery ScottBoost Price Target
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.